Massachusetts immuno-oncology startup Advantagene just raised $5 million of a proposed $35 million round, according to a regulatory filing.
The company is developing a prostate cancer vaccine called ProstAtak that’s in Phase 3 development – though its gene-mediate cytotoxic approach could be applied to several other solid tumor cancers, the company says.
ProstAtak, much like Advantagene’s other cancer immunotherapy approaches, melds radiation with its biologic to create cancer cell death. It’s also testing the drug in adult and pediatric brain cancer, pancreatic cancer, malignant pleural effusion and mesothelioma.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Phase 3 study started in 2011 and is expected to wrap up next year; it’s testing the vaccine in 711 patients.
